Docetaxel-carboplatin chemotherapy combined with cetuximab in patients with locally advanced or metastatic non small-cell lung cancer (NSCLC)-Results of the nonrandomised phase II study TaxErb

Lung Cancer

Volumn 75, Issue 3, 2012, Pages 348-352

  Fischer, J R ^a   Griesinger, F ^b   Fink, T ^c   Salm, T ^d   Marseille, A ^e   Wolf, M ^f  

^a Klinik Lowenstein   (Germany)

^b PIUS HOSPITAL   (Germany)

^c Rangauklinik Ansbach GmbH   (Germany)

^d SANOFI AVENTIS DEUTSCHLAND GMBH   (Germany)

^e HZM Pharmaservice GmbH   (Germany)

^f KLINIKUM KASSEL   (Germany)

Author keywords

Advanced; Carboplatin; Cetuximab; Docetaxel; First line; Metastatic; Non small cell lung cancer; Weekly

Indexed keywords

CARBOPLATIN; CETUXIMAB; DOCETAXEL;

ADVANCED CANCER; ALOPECIA; ANAPHYLACTIC SHOCK; ANEMIA; AREA UNDER THE CURVE; ARTICLE; ASTHENIA; BONE METASTASIS; BRAIN INFARCTION; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER STAGING; CENTRAL NERVOUS SYSTEM METASTASIS; CYTOKINE RELEASE SYNDROME; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DYSPNEA; FEBRILE NEUTROPENIA; FEMALE; HEART INFARCTION; HUMAN; HYPERTENSION; LEUKOPENIA; LIVER METASTASIS; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; METASTASIS; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAIL DISEASE; NAUSEA; NEUTROPENIA; OPEN STUDY; OVERALL SURVIVAL; PAIN; PHASE 2 CLINICAL TRIAL; PLEURA METASTASIS; PNEUMONIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SKIN TOXICITY; STAPHYLOCOCCAL BACTEREMIA; STOMATITIS; SURVIVAL RATE; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE; VOMITING;

ANEMIA; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE-FREE SURVIVAL; DYSPNEA; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; SURVIVAL RATE; TAXOIDS;

EID: 84856576793     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2011.08.006     Document Type: Article

References (46)

1. Ferlay J., Shin H.R., Bray F., Forman D., Mathers C., Parkin Dm. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010, 127:2893-2917.
2. Azzoli C.G., et al. American society of clinical oncology clinical practice guideline update on chemotherapy for stage IV non-small cell lung cancer. J Clin Oncol 2009, 27(36):6251-6266.
3. Goeckenjan G., Sitter H., Thomas M., et al. Prävention, diagnostik therapie und nachsorge des lungenkarzinoms. Pneumologie 2010, 64(Suppl. 2):e1-e164.
4. Herbst R.S., Shin D.M. Monoclonal antibodies to target epidermal growth factor receptor-positive tumors: a new paradigm for cancer therapy. Cancer 2002, 94:1593-1611.
5. Khambata-Ford S., Harbison C., Hart L., et al. Analysis of potential predictive markers of cetuximab benefit in BMS099, a phase III study of cetuximab and first-line taxane/carboplatin in advanced non-small cell lung cancer. J Clin Oncol 2010, 28:918-927.
6. Wells A. EGF receptor. Int J Biochem Cell Biol 1999, 31:637-643.
7. Yarden Y., Sliwkowski M.X. Untangling the ErbB sigaling network. Nat Rev Mol Cell Biol 2001, 2:127-137.
8. Gibson S., Tu S., Oyer R., et al. Epidermal growth factor protects epithelial cells against Fas-induced apoptosis. Requirement for akt activation. J Ciol Chem 1999, 274:17612-17618.
9. Shepherd F.A., Pereira J.R., Ciuleanu T., et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005, 353:123-132.
10. Kim E., Hirsch V., Mok T., et al. Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial. Lancet 2008, 372:1809-1818.
11. Herbst R.S., Giaccone G., Schiller J.H., et al. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial-INTACT 2. J Clin Oncol 2004, 22:785-794.
12. Giaccone G., Herbst R.S., Manegold C., et al. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial-INTACT 1. J Clin Oncol 2004, 22:777-784.
13. Gatzemeier U., Pluzanska A., Szczesna A., et al. Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small cell lung cancer: the tarceva lung cancer investigation trial. J Clin Oncol 2007, 25:1545-1552.
14. Herbst R.S., Prager D., Fehrenbacher L., et al. TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol 2005, 23:5892-5899.
15. Sequist L., Martins R.G., Spigel D., et al. Firstline gefitinib in patients with advanced non-small cell lung cancer harboring somatic EGFR mutations. J Clin Oncol 2008, 26:2442-2449.
16. Goldstein N.I., Prewett M., Zuklys K., et al. Biological efficacy of a chimeric antibody to the epidermal growth factor receptor in human tumor xenograft model. Clin Cancer Res 1995, 1:1311-1318.
17. Mukohara T., Engelman J.A., Hanna N.H., et al. Differential effects of gefitinib and cetuximab on non small-cell lung cancers bearing epidermal growth factor receptor mutations. J Natl Cancer Inst 2005, 97:1185-1194.
18. Kurai J., Chikumi H., Hashimoto K., et al. Antibody-dependent cellular cytotoxicity mediated by cetuximab against lung cancer cell lines. Clin Cancer Res 2007, 13:1552-1561.
19. Kawaguchi Y., Kono K., Mimura K., et al. Cetuximab induce antibody-dependent cellular cytotoxicity against EGFR-expressing esophageal squamous cell carcinoma. Int J Cancer 2007, 120:781-787.
20. Thienelt C.D., Bunn P.A., Hanna N., Rosenberg A., Needle M.N., Long M.E., et al. Multicenter phase I/II study of cetuximab with paclitaxel and carboplatin in untreated patients with stage IV non-small cell lung cancer. J Clin Oncol 2005, 23:8786-8793.
21. Borghaei H., Langer C.J., Millenson M., Ruth K.J., Litwin S., Tuttle H., et al. Phase II study of paclitaxel, carboplatin, and cetuximab as first line treatment, for patients with advanced non-small cell lung cancer (NSCLC): results of OPN-017. J Thorac Oncol 2008, 3:1286-1292.
22. Belani C.P., Schreeder M.T., Steis R.G., Guidice R.A., Marsland T.A., Butler E.H., et al. Cetuximab in combination with carboplatin and docetaxel for patients with metastatic or advanced-stage nonsmall cell lung cancer: a multicenter phase 2 study. Cancer 2008, 113:2512-2517.
23. Rosell R., Robinet G., Szczesna A., Ramlau R., Constenla M., Mennecier B.C., et al. Randomized phase II study of cetuximab plus cisplatin/vinorelbine alone as first-line therapy in EGFR-expressing advanced non-small cell lung cancer. Ann Oncol 2008, 19:362-369.
24. Butts C.A., Bodkin D., Middleman E.L., Englund C.W., Ellison D., Alam Y., et al. Randomized phase II study of gemcitabine plus cisplatin, with or without cetuximab, as first-line therapy for patients with advanced or metastatic non-small cell lung cancer. J Clin Oncol 2007, 25:5777-5784.
25. Herbst R.S., Chansky K., Kelly K., Atkins J.N., Davies A.M., Dakhil S.R., et al. A phase II randomized selection trial evaluating concurrent chemotherapy plus cetuximab or chemotherapy followed by cetuximab in patients with advanced non-small cell lung cancer (NSCLC): final report of SWOG 0342. J Clin Oncol 2007, 25(18S):395s. [Abstract 7545].
26. Pirker R., Pereira J.R., Szczesna A., et al. Cetuximab plus chemotherapy in patients with advanced NSCLC (FLEX): an open-label randomised phase III trial. Lancet 2009, 373:1515-1531.
27. Lynch T., Patel T., Dreisbach L., et al. Cetuximab and first-line taxane/carboplatin chemotherapy in advanced NSCLC: results of the randomised multicenter phase III trial BMS099. J Clin Oncol 2010, 28(6):911-917.
28. Bria E., Cuppone F., Ciccarese M., et al. Weekly docetaxel as second line chemotherapy for advanced non-small-cell lung cancer: meta-analysis of randomized trials. Cancer Treat Rev 2006, 32:583-587.
29. Kaira K., Tsuchiya S., Sunaga N., Yanagitani N., et al. A phase I dose escalation study of weekly docetaxel and carboplatin in elderly patients with nonsmall cell lung cancer. Am J Clin Oncol 2007, 30:51-56.
30. Ishimoto O., Sugawara S., Inoue A., et al. Phase II study of carboplatin combined with biweekly docetaxel for advanced non-small cell lung cancer. J Thorac Oncol. 2006, 1:979-983.
31. Tartarone A., Romano G., Iodice G. Cisplatin and weekly docetaxel as first-line therapy in patients with advanced non-small cell lung cancer a phase II study. Tumori 2005, 9:131-134.
32. Therasse P., Arbuck S.G., Eisenhauer E.A., Wanders J., Kaplan R.S., Rubinstein L., et al. New guidelines to evaluate the response to treatment in solid tumors. European Organisation of Research and Treatment of Cancer, National Cancer Institute of the United States, National Institute of Canada. J Natl Cancer Inst 2000, 92:205-221.
33. Simon R. Optimal two-stage designs for phase II clinical trials. Control Clin Trials 1989, 10:1-10.
34. Hotta K., Matsuo K., Ueoka H., et al. Metaanalysis of randomized clinical trials comparing cisplatin to carboplatin in patients with advanced non-small-cell lung cancer. J Clin Oncol 2004, 22:3852-3859.
35. Ardizzoni A., Boni L., Tiseo M., Fossella F.V., Schiller J.H., Paesmans M., et al. Cisplatin- versus carboplatin based chemotherapy in first-line treatment of advanced non-small-cell lung cancer: an individual patient data meta-analysis. J Natl Cancer Inst 2007, 99:847-857.
36. Fossella F., Pereira J.R., von Pawel J., et al. Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study group. J Clin Oncol 2003, 21:3016-3024.
37. Rosell R., Gatzemeier U., Betticher D.C., et al. Phase III randomised trial comparing paclitaxel/carboplatin with paclitaxel/cisplatin in patients with advanced non-small-cell lung cancer: a cooperative multinational trial. Ann Oncol 2002, 13:1539-1549.
38. Scagliotti G.V., De Marinis F., Rinaldi M., et al. Phase III randomized trial comparing three platinum based doublets in advanced non-small-cell lungcancer. J Clin Oncol 2002, 20:4285-4291.
39. Paccagnella A., Favaretto A., Oniga F., et al. Cisplatin versus carboplatin in combination with mitomycin and vinblastine in advanced non small cell lung cancer: a multicenter, randomized phase III trial. Lung Cancer 2004, 43:83-91.
40. Belani C.P., Lee J.S., Socinski M.A., et al. Randomized phase III trial comparing cisplatin-etoposide to carboplatin-paclitaxel in advanced or metastatic non-small cell lung cancer. Ann Oncol 2005, 16:1069-1075.
41. Rudd R.M., Gower N.H., Spiro S.G., et al. Gemcitabine plus carboplatin versus mitomycin, ifosfamide and cisplatin in patients with stage IIIB or IV non-small-cell lung cancer: a phase III randomized study of the London Lung Cancer Group. J Clin Oncol 2005, 23:142-153.
42. Booton R., Lorigan P., Anderson H., et al. A phase III trial of docetaxel/carboplatin versus mitomycin C/ifosfamide/cisplatin (MIC) or mitomycin C/vinblastine/cisplatin (MVP) in patients with advanced non-small-cell lung cancer: a randomised multicentre trial of the British Thoracic Oncology Group (BTOG1). Ann Oncol 2006, 17:1111-1119.
43. Belani C.P., Pereira J.R., von Pawel J., et al. Effect of chemotherapy for advanced non-small cell lung cancer on patients' quality of life: a randomized controlled trial. Lung Cancer 2006, 53:231-239.
44. O'Byrne K.J., Bondarenko I., Barrios C., Eschbach C., Martens U., Hotko Y., et al. Molecular and clinical predictors of outcome for cetuximab in non-small cell lung cancer (NSCLC): data from the FLEX study. J Clin Oncol 2009, 27(15S). [Abstract 8007].
45. Gatzemeier U., von Pawel J., Vynnychenko I., Zatloukal P., et al. First-cycle rash and survival in patients with advanced non-small-cell lung cancer receiving cetuximab in combination with first-line chemotherapy: a subgroup analysis of data from the FLEX phase 3 study. Lancet Oncol 2011, 12(January (1)):30-37.
46. Pirker R, Paz Ares L, Eberhardt WE, Krzakowski M, Störkel S, Heeger S, et al. Epidermal growth factor receptor (EGFR) expression as a predictor of survival for first-line chemotherapy plus cetuximab in FLEX study patients with advanced non-small cell lung cancer (NSCLC). In: IASLC: 14th. WCLC 2011, abstract 001.06. http://www.2011worldlungcancer.org/abstracts.